Jay Bradner, NIBR president (Jeff Rumans)
Novartis is 'all in' on siRNA, inking a new collaboration with Alnylam to develop alternative to liver transplants
Alnylam was a few years ahead in the small interfering RNA (siRNA) space when Novartis jumped on the bandwagon in early 2020, licensing the company’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.